# Kenvue Inc. (KVUE)

**Exchange:** NYSE  
**Sector:** Consumer Defensive  
**Market cap:** $34.94B  
**Price:** $18.16 (+0.61%)

> Kenvue Inc. is a global consumer health company focused on over-the-counter medicines, personal care, and wellness products for everyday use. Headquartered in Summit, New Jersey, Kenvue develops and markets a broad portfolio of well-known brands across categories such as pain relief, allergy care, cough and cold, digestive health, baby care, skincare, and oral care. Its products include widely recognized names such as Tylenol, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s, Band-Aid, and Visine, which are distributed through pharmacies, mass retailers, e-commerce platforms, and healthcare channels worldwide. Kenvue’s business is organized around meeting consumer needs in self-care and daily health routines, offering non-prescription solutions that support hygiene, symptom relief, and skin and hair health. By combining brand recognition, large-scale distribution, and consumer insight-driven product development, Kenvue plays a significant role in the consumer health market, serving households, caregivers, and professionals across multiple regions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $15.12B | $8.79B | $2.41B | $1.47B | — |
| 2024 | $15.46B | $8.96B | $1.84B | $1.03B | — |
| 2023 | $15.44B | $8.64B | $2.51B | $1.66B | — |
| 2023 | $14.95B | $8.29B | $2.67B | $2.06B | — |
| 2022 | $15.05B | $8.42B | $2.92B | $2.08B | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $27.08B | $16.31B | $10.77B | $1.06B | — |
| 2024 | $25.60B | $15.93B | $9.67B | $1.07B | — |
| 2023 | $27.85B | $16.64B | $11.21B | $1.38B | $7.69B |
| 2023 | $27.32B | $7.35B | $19.97B | $1.23B | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $2.20B | $475M | $1.72B |
| 2024 | $1.77B | $434M | $1.33B |
| 2023 | $3.17B | $469M | $2.70B |
| 2023 | $2.52B | $375M | $2.15B |
| 2022 | $334M | $295M | $39M |

Source: [CompaniesByCap](https://companiesbycap.com/company/KVUE)